NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 7.12 against a street estimate of 7.70 — a miss of 7.5%.
with an average price target of ₹919.12.
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 GRANULES INDIA LIMITED – Q1 FY27 SUMMARY --- HEADLINE NUMBERS • Revenue: ₹14,768 Mn, +22% YoY (₹12,101 Mn in Q1 FY26); flat QoQ vs ₹14,706 Mn in Q4 | 2026-07-21 |
| Quarterly results · Q1 FY27 GRANULES INDIA LIMITED - Q1 FY2026-27 RESULTS SUMMARY HEADLINE NUMBERS • Standalone Q1 FY2026-27 Revenue: Rs 8,018.77 million (down from Rs 8,768.21 | 2026-07-21 |
| Annual report FY2026 GRANULES INDIA LIMITED – FY 2025-26 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Revenue: ₹53,656 Million (+20% YoY) – crossed ₹50,000 million milestone | 2026-07-15 |
| Q4 FY26 earnings call GRANULES INDIA LIMITED – Q4 & FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year FY26 Revenue: INR 53,656 million – 20% year-on-year gro | 2026-05-05 |
| Quarterly results · Q4 FY26 GRANULES INDIA LIMITED – FINANCIAL SUMMARY Year Ended March 31, 2026 --- HEADLINE NUMBERS • Total Revenue (Standalone): Rs 30,301.63 million for FY | 2026-04-29 |
| Q3 FY26 earnings call GRANULES INDIA LIMITED – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR1,388 crores (INR13,879 million), up 22% year-on-year; up 7 | 2026-01-28 |
| Quarterly results · Q3 FY26 GRANULES INDIA LIMITED – Q3 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS STANDALONE (9 months ended 31-Dec-2025) • Revenue from operations: Rs. 25,971. | 2026-01-23 |
| Q2 FY26 earnings call GRANULES INDIA LIMITED Q2 FY'26 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 FY'26 Revenue: Rs. 12,970 million vs Rs. 9,666 million in Q2 FY'25 (34% YoY g | 2025-11-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.75 / share ex-date Jul 30, 2026 | 2026-07-30 |
| Announcement | Date |
|---|---|
| US packaging facility receives FDA EIR with no action indicated status Granules India Limited announced that its packaging facility in the United States has received FDA (Food and Drug Administration) EIR (Establishment Inspection Report) with a 'No Action Indi | 2026-03-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Granules India Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.